Get the Stockscreener App
126.22
1.36%
-1.74
After Hours:
126.22
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $126.22, with a volume of 8.63M.
It is down -1.36% in the last 24 hours and down -0.39% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
See More
Previous Close:
$127.96
Open:
$127.62
24h Volume:
8.63M
Relative Volume:
1.25
Market Cap:
$218.91B
Revenue:
$41.95B
Net Income/Loss:
$13.40B
P/E Ratio:
16.50
EPS:
7.65
Net Cash Flow:
$6.35B
1W Performance:
+1.83%
1M Performance:
-0.39%
6M Performance:
+8.76%
1Y Performance:
+15.92%
1-Day Range:
$125.59
$128.49
1-Week Range:
$120.85
$128.52
52-Week Range:
$99.71
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
126.22 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
94.23 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
346.80 | 132.37B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
82.37 | 105.64B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.76 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
“Rotation Carnage”: Jim Cramer Blames a Bad Rotation for Abbott Laboratories (ABT)’s Fall from Grace - Insider Monkey
ASML, Prologis, Abbott Labs, and more set to report earnings Wednesday - Investing.com India
Abbott Laboratories (ABT) Anticipates Modest Earnings Growth Amid Cautious Sentiment - GuruFocus
Abbott's Q1 earnings in focus as analysts see path to beat amid business strength (ABT:NYSE) - Seeking Alpha
Abbott (ABT) Leads Tomorrow's Earnings Reports Amid Market Antic - GuruFocus
How To Earn $500 A Month From Abbott Laboratories Stock Ahead Of Q1 Earnings - AOL.com
Abbott Laboratories's Earnings Outlook - Benzinga
Abbott Laboratories (ABT) Gets a Buy from Wells Fargo - The Globe and Mail
RBC Capital Boosts Abbott (ABT) Price Target Amid Strong Q1 Pros - GuruFocus
Abbott Laboratories (ABT) Q1 Earnings: What To Expect - Yahoo Finance
The Zacks Analyst Blog Abbott, Taiwan Semiconductor, American Express, ManpowerGroup and D.R. Horton - TradingView
RBC Raises Price Target on Abbott Laboratories to $140 From $135, Keeps Outperform Rating - MarketScreener
ABBOTT LABORATORIES Earnings Preview: Recent $ABT Insider Trading, Hedge Fund Activity, and More - Nasdaq
Nanomedicines Market to Witness Massive Growth by 2032 | Abbott - openPR.com
How Will Abbott Laboratories Stock React To Its Upcoming Earnings? - Trefis
Stifel maintains Abbott stock Buy rating, $135 target post-Volt data - Investing.com India
Medical Nutrition Market Key Players AnalysisAbbott - openPR.com
Older Adults Health Supplement Market May See Big Move | Abbott - openPR.com
Drug Testing Market Detailed In New Research Report 2025 | Abbott - openPR.com
What Is Abbott Laboratories's (NYSE:ABT) Share Price Doing? - Yahoo Finance
With 79% ownership of the shares, Abbott Laboratories (NYSE:ABT) is heavily dominated by institutional owners - simplywall.st
Immunoassay Analyzers Market Size to Hit USD 10.16 Billion by 2032 | SNS Insider - GlobeNewswire Inc.
Ex-Dividend Reminder: Buckle, AbbVie and Abbott Laboratories - Nasdaq
Recent Filing Shows That Rep. Josh Gottheimer Sold Over $32K Worth of Abbott Laboratories Stock - Benzinga
Seeking Clues to Abbott (ABT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics - Yahoo Finance
TD Cowen maintains Abbott Labs stock Buy rating, $135 target - Investing.com India
TD Cowen maintains Abbott Labs stock Buy rating, $135 target By Investing.com - Investing.com UK
Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus - Zacks Investment Research
Immunoassay Market to Witness Remarkable Growth with Abbott - openPR.com
Positive Outlook for Abbott Laboratories: Strong Growth and New Product Launches Support Buy Rating - TipRanks
Will Trump Tariffs Make or Break Healthcare Space? 3 Stocks to Rely On - TradingView
Abbott (ABT) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Abbott Laboratories' (NYSE:ABT) institutional investors lost 5.9% over the past week but have profited from longer-term gains - Yahoo Finance
Abbott bolsters its Heart Failure leadership - MassDevice
Cytokine Market Is Booming So Rapidly 2025-2032 -Abbott, AB - openPR.com
Oppenheimer maintains Abbott stock Outperform with $134 target By Investing.com - Investing.com India
Oppenheimer maintains Abbott stock Outperform with $134 target - Investing.com
The Zacks Analyst Blog Highlights Molson Coors, CenterPoint Energy, WEC Energy, Abbott Laboratories and HCA Healthcare - Yahoo Finance
Is Abbott Laboratories (ABT) the Most Profitable Dividend Stock to Buy Now? - Insider Monkey
Citigroup Adjusts Abbott Laboratories Price Target to $155 From $160, Maintains Buy Rating - MarketScreener
Abbott Laboratories (ABT): One of the Best Dividend Kings to Buy for Safe Dividend Growth - Insider Monkey
Abbott Laboratories (ABT) Maintains Strong ROE Amid Stock Decline - GuruFocus
Will Weakness in Abbott Laboratories' (NYSE:ABT) Stock Prove Temporary Given Strong Fundamentals? - Yahoo Finance
Here’s What to Expect From Abbott Laboratories’ Next Earnings Report - Nasdaq
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic? - Yahoo
Piper Sandler maintains Overweight on Abbott Labs with $133 target - Investing.com
Reasons to Add ABT Stock to Your Portfolio Right Now - TradingView
Q4 Rundown: Abbott Laboratories (NYSE:ABT) Vs Other Medical Devices & SuppliesDiversified Stocks - Yahoo Finance
Unsanitary Practices Persist at Baby Formula Factory Whose Shutdown Led to Mass Shortages, Workers Say - ProPublica
Leadless Pacemakers Market Deep Research 2025-2032 | Abbott - openPR.com
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):